Bevifibatide Citrate Injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Bio-Thera Solutions, Ltd.
- Medicine type
- Chemical medicine
- Therapeutic area
- Cardiovascular
- Indications recorded in the public source
- For patients with acute coronary syndrome undergoing percutaneous coronary intervention, including coronary stent implantation, to reduce the risks of acute occlusion, in-stent thrombosis, no-reflow and slow flow.
- Indication source and scope
- An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Not matched in the 2025 national list; manual review pending
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance verification notes
- No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.
Sources
- https://www.cnpharm.com/upload/resources/file/2025/03/18/170990.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.bio-thera.com/files/specification/3-240F3143446.pdf
Open the interactive record, public price references and discussions